TFFP: TFF Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 6.41
Enterprise Value ($M) 3.20
Book Value ($M) 5.30
Book Value / Share 1.71
Price / Book 1.21
NCAV ($M) 0.98
NCAV / Share 0.32
Price / NCAV 6.54

Profitability (mra)
Return on Invested Capital (ROIC) -3.69
Return on Assets (ROA) -1.09
Return on Equity (ROE) -1.20

Liquidity (mrq)
Quick Ratio 1.26
Current Ratio 1.26

Balance Sheet (mrq) ($M)
Current Assets 4.86
Assets 9.19
Liabilities 3.88
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.73
Operating Income -21.89
Net Income -21.24

Cash Flow Statement (mra) ($M)
Cash From Operations -16.04
Cash from Investing -0.09
Cash from Financing 5.01

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
05-08 13G Intracoastal Capital, Llc 4.99
05-08 13G/A Carlson Capital L P 9.12 -88.17
02-14 13G/A Lytton Laurence W 0.10 -99.62

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-03-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13
2023-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-24 12,043 29,899 40.28
2024-05-23 35,295 114,851 30.73
2024-05-22 2,129 690 308.55
2024-05-21 14,987 3,336 449.25
2024-05-20 13,579 9,929 136.76

(click for more detail)

Similar Companies
TCRT – Alaunos Therapeutics, Inc. TELO – Telomir Pharmaceuticals, Inc.
TENX – Tenax Therapeutics, Inc. TGTX – TG Therapeutics, Inc.
THAR – Tharimmune, Inc.


Financial data and stock pages provided by
Fintel.io